MacroGenics Sells GMP Manufacturing Arm to Bora Pharmaceuticals for $122.5M
Event summary
- MacroGenics sold its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million.
- The deal includes the transfer of MacroGenics’ Rockville and Frederick facilities, along with approximately 140 employees.
- Bora will support process development and drug substance production for MacroGenics’ pipeline under a supply agreement.
The big picture
This transaction reflects a broader trend in biotech where clinical-stage companies divest non-core assets to streamline operations and focus on drug development. The $122.5 million deal underscores Bora’s expansion strategy in biologics manufacturing, positioning it as a key player in the CDMO space.
What we're watching
- Operational Integration
- How Bora will integrate MacroGenics’ manufacturing operations and maintain production continuity for clinical and commercial needs.
- Financial Flexibility
- Whether the $122.5 million divestiture provides MacroGenics with sufficient financial runway to advance its pipeline.
- Strategic Focus
- The pace at which MacroGenics shifts resources toward R&D and partnerships following the sale of its manufacturing arm.